Lydia Scarfò describes prophylactic and therapeutic measures against SARS-CoV-2 in patients with CLL, potential risk factors for mortality, seroconversion in response to vaccination and areas of research and unmet need regarding prevention and treatment of COVID-19 infections in patients with CLL and hematologic malignancies in general. Finally, she gives insights into the clinical implications of XPO1 mutations in CLL patients.

Here is the full iwCLL 2023 report.